News Column

ALK Abello [ALK B] to Ring The NASDAQ Stock Market Closing Bell

May 22, 2014



ADVISORY, May 22, 2014 (GLOBE NEWSWIRE) --

What:

ALK Abello [ALK B], a speciality pharmaceutical company with two newly FDA approved allergy immunotherapy products will visit the NASDAQ MarketSite in Times Square.

In honor of the occasion, Jens Bager, President and CEO will ring the Closing Bell.

Where:

NASDAQ MarketSite – 4 Times Square – 43rd & BroadwayBroadcast Studio

When:

Friday, May 23, 20143:45 p.m. to 4:00 p.m. ET         

ALK Abello Contact:

Martin Barlebo

+45 20 64 11 43

mbrdk@alk.net

NASDAQ MarketSite:

Christine Barna

(646) 441-5310

Christine.Barna@nasdaqomx.com

Feed Information:

Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West

18 mhz Lower

DL 3811 Vertical

FEC 3/4

SR 13.235

DR 18.295411

MOD 4:2:0

DVBS QPSK

Social Media:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ.

For photos from ceremonies and events visit our Instagram Page: http://instagram.com/nasdaq.

For news tweets, please visit our Twitter page at: http://twitter.com/nasdaqomx.

For exciting viral content and ceremony photos visit Tumblr Page: http://nasdaq.tumblr.com/.

Webcast:

A webcast of the NASDAQ Closing Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx.

Photos:

To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.      

About ALK Abello [ALK B]:

ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is the world leader in allergy immunotherapy – a unique treatment of the underlying cause of allergy. The company has approximately 1,800 employees with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with Merck and Torii to commercialise sublingual allergy immunotherapy tablets in North America and Japan, respectively. The company is headquartered in HØrsholm, Denmark, and listed on NASDAQ OMX Copenhagen. Find more information at www.alk.net.

About NASDAQ OMX Group:

NASDAQ OMX (Nasdaq:NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, NASDAQ OMX enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. NASDAQ OMX is home to more than 3,400 listed companies with a market value of over $8.5 trillion and more than 10,000 corporate clients. To learn more, visit www.nasdaqomx.com.

-NDAQA-

company logo

Source: The NASDAQ OMX Group, Inc.


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: GlobeNewswire


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters